Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission

Pretransplant measurable residual disease (MRD) has been shown to be associated with relapse incidence following allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). However, it remains less clear whether pretransplant MRD status affects transplant outcomes in core b...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2021-11, Vol.56 (11), p.2779-2787
Main Authors: Konuma, Takaaki, Kondo, Tadakazu, Masuko, Masayoshi, Shimizu, Hiroaki, Shiratori, Souichi, Fukuda, Takahiro, Kato, Jun, Sawa, Masashi, Ozawa, Yukiyasu, Ota, Shuichi, Uchida, Naoyuki, Kanda, Yoshinobu, Kako, Shinichi, Fujisawa, Shin, Fukushima, Kentaro, Ichinohe, Tatsuo, Atsuta, Yoshiko, Yanada, Masamitsu
Format: Article
Language:English
Subjects:
631/67/1990
692/308/2171
Acute myeloid leukemia
Binding
Cell Biology
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic stem cells
Homografts
Humans
Internal Medicine
Leukemia
Leukemia, Myeloid, Acute
Medicine
Medicine & Public Health
Mortality
Multivariate analysis
Myeloid leukemia
Neoplasm, Residual - therapy
Patient outcomes
Patients
Polymerase chain reaction
Prognosis
Public Health
Remission
Remission (Medicine)
Retrospective Studies
Runx1 protein
Stem cell transplantation
Stem Cells
Subgroups
Transplantation
Transplantation, Homologous
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pretransplant measurable residual disease (MRD) has been shown to be associated with relapse incidence following allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). However, it remains less clear whether pretransplant MRD status affects transplant outcomes in core binding factor AML (CBF-AML). We retrospectively evaluated the effect of pretransplant MRD, which was measured by a polymerase chain reaction of RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcripts, on transplant outcomes for a cohort of 959 adult patients with t (8;21) or inv(16) AML treated by allogeneic HCT during complete remission (CR), between 2000 and 2018. Multivariate analysis showed the absence of pretransplant MRD was significantly associated with lower relapse (hazard ratio [HR], 0.46; P  
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-021-01409-4